MDA 2022 poster: Associations between steroid treatment and clinical outcomes among non-ambulatory patients with Duchenne muscular dystrophy (DMD)
This poster, presented at the 2022 MDA Conference in Nashville, Tennessee, USA, reports the results of a comparison of corticosteroid treatments on clinical outcomes in non-ambulatory DMD patients
Review the background and design of an analysis to determine clinical outcomes of corticosteroid treatment in 86 non-ambulatory DMD patients, from the PRO-DMD-01 study
Explore the results, showing the effects of corticosteroids on pulmonary, cardiac, and functional progression of DMD following loss of ambulation
Deflazacort is a corticosteroid indicated for the treatment of DMD in patients 2 years of age and older. PTC Therapeutics is the Marketing Authorization Holder for deflazacort in the US only. Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The US Prescribing Information for deflazacort is available here. Please refer to your local country guidance for more information.
For medical information, product complaints, or to report an adverse event, please call 1-866-562-4620 or email at firstname.lastname@example.org. You may also report adverse events directly to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200045 I August 2023
Sign in or register to access exclusive content on this site